CD19 and chronic myelogenous leukemia, BCR-ABL1 positive: CD19-CAR T cells successfully targeted imatinib-resistant blasts, highlighting CD19-CAR T cells as a potentially effective strategy in BP-CML specially CD19-positive RUNX1mut BP-CML patients.